AbbVie, a research-based global biopharmaceutical company, and Allergan plc, a global pharmaceutical company, announced that they have entered into a consent decree agreement with staff of the U.S. Federal Trade Commission (FTC) regarding AbbVie’s pending acquisition of Allergan.
Under the terms of the consent decree, the companies have agreed to divest brazikumab, an investigational IL-23 inhibitor in development for autoimmune diseases, to AstraZeneca and Zenpep, a treatment for exocrine pancreatic insufficiency due to cystic fibrosis and other conditions, to Nestle. Nestle also will be acquiring Viokace, another pancreatic enzyme preparation, as part of the same transaction.
The consent decree, including the proposed purchasers, remains subject to further review and approval by the Commissioners of the FTC. The parties anticipate closing in May 2020.